ParaPRO: Innovations in Life Sciences

ParaPRO Press Release

Date: June 12, 2009 Back
Contact: Bill Culpepper III, President, 317-216-8166, billc@parapro.com

ParaPRO LLC Hires Pharmaceutical Industry Channel Veteran to Support the Anticipated Launch of NatrOVATM brand (Spinosad), a prescription drug under FDA review for the treatment of Head Lice

David Bedich Joins ParaPRO from TOMedica Solutions as Director of Trade Commercialization and Reimbursement

CARMEL, IN, June 12, 2009 – ParaPRO LLC announced today that it has hired David Bedich to serve as Director of Trade Commercialization and Reimbursement.  ParaPRO, based in Carmel, Indiana, is a new pharmaceutical enterprise and a wholly owned subsidiary of the SePRO Corporation.  ParaPRO previously submitted to the FDA for review a New Drug Application for NatrOVA™ brand (Spinosad), for the treatment of pediculosis capitis (Head Lice).

Bedich joins ParaPRO's senior executive team reporting directly to ParaPRO’s president, William Culpepper.  “David Bedich is approaching 20 years of experience within the pharmaceutical industry and brings to ParaPRO solid relationships with many of the channel partners that will be critical for the company's success,” said Mr. Culpepper.  He went on to share, “after completing an extended consulting project for us, it became apparent that adding David as a permanent member of our team was the right move for ParaPRO."

Bedich will play a critical role in developing and executing a trade and reimbursement strategy for ParaPRO.  Upon joining ParaPRO, Bedich said, "I am excited about joining the ParaPRO team and being a part of an innovative group that is focused on developing a new approach to the treatment of head lice.”

Bedich’s years of experience span across the pharmaceutical industry holding leadership positions with Schering Plough, Schwarz Pharma, Biovail, Cardinal Commerce and Esprit Pharma.  Most recently, Bedich served as President of TOMedica Solutions, where he was responsible for the creation and development of this division of the F. Dohmen Company.

About Spinosad
Spinosad, the active ingredient upon which NatrOVA™ is based, is a non-synthetic, fermentation product of the soil bacterium Saccharopolyspora spinosa. Several products containing Spinosad have been approved by the U.S. Environmental Protection Agency (EPA) for use on agricultural crops and by the Organic Materials Review Institute for use on organically grown crops. The Spinosad technical bulletin provides an extensive overview of Spinosad.

About ParaPRO LLC
ParaPRO LLC was founded in 2002 when SePRO Corporation of Carmel, IN purchased the worldwide rights to develop and market Spinosad for the control of lice in human health from Eli Lilly and Company. The compound is currently in clinical trials at multiple sites across the United States. More information on ParaPRO can be found at www.parapro.com.




Ask your doctor if Natroba™ Topical Suspension is right for you or your child.

INDICATION
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

ADJUNCTIVE MEASURES
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
  • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
  • Wash personal care items such as combs, brushes, and hair clips in hot water
A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

IMPORTANT SAFETY INFORMATION
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

Consult the Patient Information, Full Prescribing Information and your doctor for more complete information on Natroba™ Topical Suspension.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.